Investing in Pharmaceuticals and Biotech
The Pharma & Biotech market has generated very attractive returns for many investors, but at the same time has produced losses to other investors. The sector contains a large number of extra-high risk companies, many of which are founded on weak foundations and pursuing projects that are unlikely to either reach the market or to be seen as attractive opportunities by big pharma companies for commercialisation. The professional large investors recently focus much more on mature companies with products and a pipeline.
Small, private companies may be able to progress development of their compounds or technologies up to a point, but are very unlikely to be able to commercialise pharmaceutical products on their own on a worldwide basis, as they will not be able to set up the infrastructure for marketing and distribution. As a result, the vast majority of biotech companies will need corporate deals with pharma companies that have the means to commercialise on a large scale and around the world.
Market Research and Analysis
Exiting through corporate deals
Industry Experience, Proven Track Record, Highly-Capable and Results-Driven
We can assist investors' portfolio companies deliver corporate deals that may facilitate exit and provide validation for the public markets. Investing in the Life Sciences sector is inherently a high risk process. Expert industry knowledge is essential to mitigate risk and ensure the right decisions are made.
Supporting Professional Investors in the Sector
Considering going into an investment? Needing independent research? Wanting a corporate deal for a portfolio company? Planning to exit an investment?